Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors

Dermatologic Surgery

Volumn 35, Issue 11, 2009, Pages 1766-1770

  Smith, Kathleen J ^a   Haley, Heather ^b   Hamza, Sate ^c   Skelton, Henry G ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b Haley Dermatology   (United States)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG INHIBITION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALE; MELANOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SKIN BIOPSY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KERATOACANTHOMA; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROTEIN KINASE INHIBITORS; PYRIDINES; SKIN NEOPLASMS;

EID: 72349096392     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2009.01289.x     Document Type: Article

References (19)

1. Shchemelinim I, Sefc L, Necas E. Protein kinase inhibitors. Folia Biol 2006 52 : 137 148.
2. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005 4 : 677 685.
3. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006 31 : 783 785.
4. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007 56 : 171 172.
5. Kobayashi K, Pezen DS, Vogaelzang NJ, et al. Keratoacanthoms and skin neoplasms associated with suramin therapy. Arch Dermatol 1996 132 : 96 8.
6. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007 1775 : 21 62.
7. El-Abaseri TB, Putta SM, Hansen LA. Ultraviolet irradiation induces kertinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 2006 27 : 225 231.
8. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 2006 213 : 213 217.
9. Appel S, Balabanov S, Brummendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cell 2005 23 : 1082 1088.
10. Raniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006 116 : 26633 26642.
11. Puxeddu W, Knauf JA, Daror MA, et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocrine-Related Cancer 2005 12 : 319 334.
12. Zhang Y-L, Keng Y-F, Zhao Y, et al. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatase. J Biol Chem 1998 273 : 12281 12287.
13. Kenner JR, Sperling LC, Waseluko J, et al. Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer. J Urol 1997 158 : 2245 2246.
14. Corominas M, Kamino H, Leon J, Pellicer A. Oncogene activation in human benign tumors of skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation. Proc Natl Acd Sci USA 1989 86 : 6372 6376.
15. Leon J, Kamino H, Steinberg JJ, Pellicer A. H-ras activation in benign and self-regressing skin tumors (keratoacanthomas) in both humans and an animal model system. Mol Cell Biol 1988 8 : 786 793.
16. Corominas M, Sloan SR, Leon J, et al. Ras activation in human tumors and in animal model systems. Environ Health Perspect 1991 93 : 19 25.
17. Pruitt K, Pruitt WM, Bilter GK, et al. Raf independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for ras transformation. J Biol Chem 2002 277 : 31808 31817.
18. Zebedee Z, Hara E. Id proteins in cell cycle control and cellular senescence. Oncogene 2001 20 : 8317 8325.
19. Hussein MR. Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol 2005 32 : 191 205.